| Document |
Document Title |
|
WO/2024/071043A1 |
Provided is a novel production method of a hetero that enables the production of a heteromultimeric protein such as a bispecific antibody. The production method of the present disclosure, which is for producing a heteromultimeric prote...
|
|
WO/2024/064079A1 |
Cells may be grown in a bioreactor, and the cells may be activated by an activator (e.g., a soluble activator complex). Nutrient and gas exchange capabilities of a closed, automated cell expansion system may allow cells to be seeded at r...
|
|
WO/2024/061356A1 |
The present invention provides an interfering RNA targeting microtubule protein β2 (TUBB2). The interfering RNA can reduce the expression of TUBB2, thereby treating a disease related to the increase of TUBB2 expression or excessive prol...
|
|
WO/2024/063818A2 |
Methods for generating pre-oligodendrocyte progenitor cells (pre-OPCs), oligodendrocyte progenitor cells (OPCs) and pre-myelinating oligodendrocytes (preOLs) from human pluripotent stem cells are provided using chemically-defined culture...
|
|
WO/2024/062258A1 |
The present disclosure provides methods for preparing functionalised polysaccharide beads. One aspect provides a method for preparing functionalised cellulose beads. Also provided are a method for attaching cells to said functionalised p...
|
|
WO/2024/060269A1 |
The present invention relates to the field of cell model application, and particularly, to a mammal-derived cell model and use thereof in screening and/or preparing an anti-aging drug, a natural product, a healthcare food, and an additiv...
|
|
WO/2024/060424A1 |
Disclosed are a CAR-T cell secreting BiTE and use thereof, and particularly disclosed is a chimeric antigen receptor secreting BiTE. The chimeric antigen receptor comprises a leader peptide, a nanobody targeting mesothelin, an extracellu...
|
|
WO/2024/060465A1 |
The present invention provides a construction method and use of a gastruloid stem cell line. A gastruloid stem cell that can be stably passaged is established in this research, which retains the potential of stem cells to a certain exten...
|
|
WO/2024/061279A1 |
The present disclosure provides a recombinant bispecific antibody comprising i) a TSLP binding domain, and ii) an IL4R binding domain. The present disclosure provides a nucleic acid molecule encoding the recombinant bispecific antibody, ...
|
|
WO/2024/060484A1 |
Provided are a method for preparing a hemogenic endothelium cell and a method for preparing a hematopoietic stem cell, comprising inducing expression of transcription factors LCOR, HOXA9, HOXA5, RUNX1, and ERG at a specific period of tim...
|
|
WO/2024/063531A1 |
The present invention relates to mature intestinal organoid-derived mesenchymal stromal cells, and a use thereof. The mature intestinal organoid-derived mesenchymal stromal cells according to the present invention can act directly on a l...
|
|
WO/2024/063484A1 |
The present invention relates to a pharmaceutical composition containing Cbfβ (Core-binding factor subunit beta) expressing vascular smooth muscle cells or a culture fluid thereof as an active ingredient for the prevention or treatment ...
|
|
WO/2024/060462A1 |
Provided are a composition for promoting osteogenic differentiation of a mesenchymal stem cell, a method, and bone repair use. Specifically, a treatment product obtained by treating collagen with a HtrA3 protein solves the problem of lim...
|
|
WO/2024/061314A1 |
Provided is a transposon system, comprising a transposase and a transposon. The transposase is a mutant transposase or a fusion transposase. Compared with a wild-type ZB transposase as shown by SEQ ID NO: 1, the mutant transposase has on...
|
|
WO/2024/064792A2 |
The present disclosure relates to a composition for three-dimensional cell and/or organoid culture, comprising a phase-changing matrix comprising a partially ordered polypeptide, and a plurality of cells encapsulated in the matrix. In em...
|
|
WO/2024/062300A1 |
The present disclosure provides a biodegradable elastomer with superior characteristics comprising a polyester segment, a polycarbonate segment and a polyurethane segment.
|
|
WO/2024/060463A1 |
The present invention relates to an optimized polynucleotide sequence encoding a human coagulation factor VIII (FVIII) polypeptide. The present disclosure also relates to an FVIII gene expression cassette, a recombinant AAV vector, and a...
|
|
WO/2024/064769A1 |
The disclosure relates, in some aspects, to methods and compositions for production of immunogenic compositions. In some embodiments, the disclosure provides T cells which have been treated ex vivo with one or more oligonucleotide agents...
|
|
WO/2024/064958A1 |
Disclosed herein are methods of culturing immune cells in a medium comprising at least about 5 mM potassium ion, wherein the medium is capable of increasing the stemness of the immune cells. In some aspects, the immune cells which are cu...
|
|
WO/2024/061369A1 |
Provided is a mammalian derived cell model which can be used in anti-aging drugs. The mammalian-derived extracembryonic trophoblast cell model is an early mammalian-derived extracembryonic stage. The change model of differentiation of ce...
|
|
WO/2024/060577A1 |
The present invention relates to an armored CAR-T cell expressing interleukin 15 receptor α and interleukin 15 and immunotherapeutic use thereof.
|
|
WO/2024/060460A1 |
Provided are a stem cell-derived gastruloid model, a method for constructing same, and use. The gastruloid model is acquired by means of in vitro construction from a human pluripotent stem cell. The model can simulate biological events o...
|
|
WO/2024/060205A1 |
Disclosed are a nucleic acid molecule comprising an alternative splicing regulatory element and a target gene located at the 3' terminus of the alternative splicing regulatory element, a transcript of the nucleic acid molecule, a vector ...
|
|
WO/2024/064952A1 |
Disclosed herein are methods of culturing immune cells in a medium comprising at least about 5 mM potassium ion, wherein the medium is capable of increasing the sternness of the immune cells. In some aspects, the immune cells which are c...
|
|
WO/2024/060422A1 |
Disclosed are a double-targeting CAR-T cell targeting mesothelin and an NKG2D ligand and use thereof, and particularly disclosed is a chimeric antigen receptor, which comprises a nanobody targeting mesothelin and a protein targeting an N...
|
|
WO/2024/061984A1 |
The invention relates to methods of forward programming an induced pluripotent stem cell (iPSC) into a somatic cell, said methods comprising at least dual targeting of safe harbour sites in the genome of an iPSC. The invention also inclu...
|
|
WO/2024/063533A1 |
The present invention relates to a high-performance mature human intestinal organoid regenerative therapeutic agent derived from pluripotent stem cells. The high-performance mature human intestinal organoid regenerative therapeutic agent...
|
|
WO/2024/059901A1 |
The invention is directed to compositions and methods for preventing or rescuing exhaustion of immune effector cells, especially CAR T cells. The compositions and methods comprise bispecific polypeptides with a first antigen binding prot...
|
|
WO/2024/060485A1 |
Provided herein are a method for preparing a hematopoietic stem cell or a hematopoietic stem and progenitor cell, and a method for culturing a long-term hematopoietic stem cell. The method for preparing a hematopoietic stem cell or a hem...
|
|
WO/2024/063999A1 |
Disclosed herein are methods of generating intestinal organoids (IO) with immune cells (iIO) and methods of making an iIO with activated immune cells. IO compositions including immune cells, optionally including activated immune cells, (...
|
|
WO/2024/063110A1 |
The present invention addresses the problem of providing an evaluation method of a test substance using an M cell model similar to M cells in a living human body. Provided is an evaluation method of a test substance, the method including...
|
|
WO/2024/059942A1 |
It is provided a cell macroencapsulation device for implanting cells in a recipient comprising cells encapsulated in a porous membrane, wherein the porous membrane consists of a sugar network coated with a polymeric solution comprising p...
|
|
WO/2024/064824A2 |
Genetically modified NK cells and pharmaceutical compositions and methods of use thereof for treating subjects having diseases or disorders. In some forms, the genetically modified NK cells have reduced or abrogated expression of the Cal...
|
|
WO/2024/061306A1 |
The present application discloses antibodies and antibody derivatives that bind to B7H3 (also known as CD276) and methods of using the same. The antibodies or antibody derivatives comprise a single domain antibody that binds to B7H3.
|
|
WO/2024/063020A1 |
Provided is an intervertebral disc therapeutic agent having favorable post-transplant engraftment. This intervertebral disc therapeutic agent contains scaffold-free artificial tissue in which synovium-derived mesenchymal stem cells form ...
|
|
WO/2024/064261A1 |
Embodiments of the present disclosure pertain to modified cells that include a fusion protein of NPC intracellular cholesterol transporter 2 protein (NPC2) and another protein. Additional embodiments of the present disclosure pertain to ...
|
|
WO/2024/061354A1 |
The present invention provides an interfering RNA targeting TOP1 gene. The interfering RNA can reduce the expression of TOP1, thereby treating a disease related to TOP1 expression. The present invention further provides a lipid nanoparti...
|
|
WO/2024/064160A1 |
Microphysiological platforms are configured for measuring kinetic rates relating to drug absorption. These kinetic rates include GI region-specific kinetic rates of drug absorption. The kinetic rates include bioavailability of the drug o...
|
|
WO/2024/060140A1 |
The present invention relates to a novel chimeric antigen receptor specifically binding to EGFRvIII and use thereof.
|
|
WO/2024/061759A1 |
The present invention relates to stabilized HCoV-NL63 S proteins, or fragments thereof, nucleic acid sequences encoding such proteins, as well as to uses thereof.
|
|
WO/2024/056738A1 |
The present invention relates to an allogeneic myeloid cell, such as a macrophage, for use in therapy, such as the treatment of cancer in a human patient, wherein the allogeneic myeloid cell, such as the allogeneic macrophage, comprises ...
|
|
WO/2024/058589A1 |
The present invention relates to a chimeric antigen receptor (CAR) cell prepared using genetic scissor knock-in, and a use thereof, and more specifically to a method for preparing a single guide RNA (sgRNA) for TGF beta receptor 2 (TGFBR...
|
|
WO/2024/059787A1 |
The application relates to modified immune effector cells with enhanced immune cell function, as well as related pharmaceutical compositions. The application further relates to methods for generating the modified immune effector cell and...
|
|
WO/2024/058155A1 |
The present invention addresses the problem of providing a new method for simply and efficiently producing linear covalently closed DNA. Provided is a double stranded circular DNA vector, wherein the double stranded circular DNA vector...
|
|
WO/2024/059776A2 |
Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic islet cells. In some aspects, the methods provided herein relate to generation of pancreatic β cell, α cell, δ cells, and EC cells ...
|
|
WO/2024/058511A1 |
The present invention relates to a method for differentiating stem cells into hard tissue, and uses different cell culture supports during differentiation so that differentiation into hard tissue can be induced through different cell dev...
|
|
WO/2024/055077A1 |
The invention relates to fusion proteins and uses thereof for obtaining and isolating enriched populations of immune cells. Exemplified fusion proteins include those comprising a dysfunctional purinergic P2X7 receptor (P2X7R) epitope moi...
|
|
WO/2024/058198A1 |
Provided is a production method which is for induced pluripotent stem cells and by which induced pluripotent stem cells having high undifferentiation properties and differentiation potency are easily obtained. A production method for i...
|
|
WO/2024/057892A1 |
The present invention addresses the problem of providing a means for maintaining and enhancing the anti-tumor activity of TADC in a tumor microenvironment. It was found that when a composition, "cPLs adjuvant," containing three types o...
|
|
WO/2024/059208A2 |
The invention disclosed herein generally relates to methods and systems for growing, expanding and/or obtaining human intestinal organoids (HIOs) having a serosal mesothelial layer. In particular, the invention disclosed herein relates t...
|
